Excision Bio has illustrated the possibility in developing a curative gene therapy using CRISPR in treating both active and latent HSV infection in the body. The company has stated that they plan to begin clinical trials in Q1 2023. Excision’s cutting edge CRISPR gene therapy platform is built on technology licensed from the Doudna LabContinue reading “Current Herpes Cure Research at Excision BioTherapeutics”